STAT+: After a rough stretch, mRNA gets a boost — at least for now
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.
The mRNA technology behind Moderna and BioNTech's Covid-19 vaccines, which has experienced a series of ups and downs, is now seeing renewed optimism. Recently, clinical successes with personalized mRNA melanoma vaccines from Moderna and Merck have sparked hope for a more stable future for the field. Ryan Sullivan, a physician and immunologist at Mass General Brigham who has worked with Moderna, expressed cautious optimism about the potential impact of this technology.
He noted that while widespread acceptance may not be immediate, personalizing the vaccine for cancer could help change perceptions and reduce the stigma often associated with vaccines. The mRNA approach allows scientists to direct cells to produce specific proteins by altering the mRNA's genetic code, a method that facilitated the rapid development of Covid vaccines in record time.
Assistance from Operation Warp Speed, a program spearheaded by the Trump administration, also played a crucial role in accelerating vaccine development. Despite lingering skepticism, the recent progress in mRNA cancer vaccines may provide a much-needed boost for the technology's future.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
